Treatment(s) already received-Hormonal therapy Posts on Medivizor
Navigation Menu

Treatment(s) already received-Hormonal therapy Posts on Medivizor

Searching for patients with metastatic breast cancer to trial a targeted therapy

Searching for patients with metastatic breast cancer to trial a targeted therapy

Posted by on Dec 15, 2020 in Breast cancer | 0 comments

In a nutshell This phase 2 clinical trial is evaluating the safety and effectiveness of targeted therapy TAS-120 (futibatinib) alone or in combination with fulvestrant (Faslodex) in patients with metastatic breast cancer (mBC). The main outcomes to be evaluated will be the response rate and survival without cancer worsening. The details Breast...

Read More

Longer-term outcomes for olaparib in the treatment of advanced castration-resistant prostate cancer

Longer-term outcomes for olaparib in the treatment of advanced castration-resistant prostate cancer

Posted by on Oct 24, 2020 in Prostate cancer | 0 comments

In a nutshell This study evaluated longer-term survival rates and the safety of olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer (mCRPC). It found that treatment with olaparib led to significantly longer survival, especially in men with gene alterations. Some background CRPC is an especially aggressive...

Read More

Quality of life in patients with metastatic prostate cancer under cabazitaxel treatment

Quality of life in patients with metastatic prostate cancer under cabazitaxel treatment

Posted by on Oct 10, 2020 in Prostate cancer | 0 comments

In a nutshell The study compared the quality of life (QoL) of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (Jevtana) compared to abiraterone (Zytiga) or enzalutamide (Xtandi). The authors found that cabazitaxel did not reduce QoL in such patients. Some background Patients with mCRPC...

Read More

Does enzalutmide improve survival in nonmetastatic, castration-resistant prostate cancer?

Does enzalutmide improve survival in nonmetastatic, castration-resistant prostate cancer?

Posted by on Jun 21, 2020 in Prostate cancer | 0 comments

In a nutshell The study assessed whether enzalutamide (Xtandi) plus androgen deprivation therapy (ADT) increased overall survival (OS) of patients with nonmetastatic, castration-resistant prostate cancer (CRPC). The study found improved survival in patients with CRPC treated with enzalutamide. Some background ADT is a type of hormonal therapy...

Read More

How effective are therapies to prevent bone loss in patients with breast cancer?

How effective are therapies to prevent bone loss in patients with breast cancer?

Posted by on May 30, 2020 in Breast cancer | 0 comments

In a nutshell This study examined the effectiveness of three commonly used therapies to prevent bone loss in patients with hormone-positive breast cancer (BC). The results showed that the therapies prevented bone loss and fractures but to different degrees. Some background Many patients with BC are classified as hormone-positive. This means...

Read More

Gabapentin and pregabalin for hot flushes in women with breast cancer receiving hormonal therapy

Posted by on Jan 21, 2020 in Breast cancer | 0 comments

In a nutshell This study wanted to find out if two medications, gabapentin (Neurontin) and pregabalin (Lyrica) helped relieve symptoms of hot flushes and night sweats in postmenopausal women and women with breast cancer receiving hormonal therapy. The study found that gabapentin reduced the frequency of hot flushes in these women. Some background...

Read More

Quality of life in patients with advanced prostate cancer after apalutamide treatment

Posted by on Jan 12, 2020 in Prostate cancer | 0 comments

In a nutshell This study analyzed the health-related quality of life (HRQOL) in patients with metastatic castration-sensitive prostate cancer (MCSPC) after treatment with apalutamide (Erleada) and androgen deprivation therapy (ADT). The study found that apalutamide plus ADT was well tolerated and improved survival compared to ADT alone in these...

Read More

Evaluating the order of hormone therapy drugs for patients with prostate cancer

Posted by on Jan 5, 2020 in Prostate cancer | 0 comments

In a nutshell This study evaluated the order of treatment with two different hormone therapy drugs in patients with castration-resistant prostate cancer that has spread. This study found that treatment with abiraterone acetate (Yonsa) then enzalutamide (Xtandi) delayed cancer growth or spread longer than the same drugs in the opposite...

Read More

Evaluating the outcomes of cabazitaxel treatment for patients with prostate cancer

Posted by on Nov 26, 2019 in Prostate cancer | 0 comments

In a nutshell This study examined the effectiveness of cabazitaxel (Jevtana) in patients with prostate cancer that has spread. This study concluded that cabazitaxel improved patient outcomes more than conventional hormone therapy. Some background Androgen deprivation therapy (ADT) remains a standard treatment for patients with prostate cancer....

Read More

Looking for patients with advanced prostate cancer to test a new treatment

Posted by on Sep 10, 2019 in Prostate cancer | 0 comments

In a nutshell This phase 1/2 trial is examining the effectiveness of treatment with GB1275 alone or in combination with immunotherapy in patients with advanced solid tumors such as prostate cancer. The main outcome to be measured will be dose toxicity and tumor response to the treatment. This study is being conducted in Tennessee and Texas, US. The...

Read More

Searching for patients with metastatic castration resistant prostate cancer to test a targeted therapy option

Posted by on Jun 24, 2019 in Prostate cancer | 0 comments

In a nutshell This phase 2 trial is examining the effectiveness and safety of trametinib (Mekinist) in patients with metastatic castration-resistant prostate cancer (mCRPC; prostate cancer which has spread from its original place to another area in the body and keeps growing even when the amount of testosterone in the body...

Read More